Pharmacological treatment of dementia: A scoping review of systematic reviews

Dementia and Geriatric Cognitive Disorders

Volumn 36, Issue 3-4, 2013, Pages 211-228

  Van De Glind, Esther M M ^a,b   Van Enst, Wynanda A ^b   Van Munster, Barbara C ^a,d   Olde Rikkert, Marcel G M ^e   Scheltens, Philip ^c   Scholten, Rob J P M ^b   Hooft, Lotty ^b  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^d GELRE HOSPITALS   (Netherlands)

^e RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Alzheimer's disease; Dementia; Evidence based medicine; Frontotemporal dementia; Lewy body disease; Parkinson dementia; Pharmacological treatment; Scoping review; Systematic reviews; Vascular dementia

Indexed keywords

ANALGESIC AGENT; ANTIANDROGEN; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIHYPERTENSIVE AGENT; BENZODIAZEPINE; CHOLINESTERASE INHIBITOR; CYANOCOBALAMIN; CYPROTERONE; DONEPEZIL; FOLIC ACID; GALANTAMINE; GINKGO BILOBA EXTRACT; HALOPERIDOL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEDROXYPROGESTERONE ACETATE; MELATONIN; MEMANTINE; NEUROLEPTIC AGENT; NIMODIPINE; NONSTEROID ANTIINFLAMMATORY AGENT; NOOTROPIC AGENT; NORADRENALIN UPTAKE INHIBITOR; PLACEBO; RIVASTIGMINE; SELEGILINE; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VALPROIC ACID;

AGGRESSION; AGITATION; ALZHEIMER DISEASE; BEHAVIOR; CEREBROVASCULAR DISEASE; COGNITION; COGNITIVE DEFECT; CYANOCOBALAMIN DEFICIENCY; DAILY LIFE ACTIVITY; DEMENTIA; DEPRESSION; DIET SUPPLEMENTATION; DISEASE ASSOCIATION; DISEASE COURSE; DRUG COST; DRUG DOSAGE FORM COMPARISON; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EVIDENCE BASED MEDICINE; FRONTOTEMPORAL DEMENTIA; GASTROINTESTINAL TOXICITY; HORMONAL THERAPY; HUMAN; INSTITUTIONALIZATION; LEWY BODY; MEDICAL RESEARCH; MENTAL DISEASE; META ANALYSIS (TOPIC); MINI MENTAL STATE EXAMINATION; MONOTHERAPY; MORBIDITY; MULTIINFARCT DEMENTIA; NAUSEA AND VOMITING; NEUROPROTECTION; NURSING HOME PATIENT; OFF LABEL DRUG USE; OUTCOMES RESEARCH; PAIN; PARKINSON DISEASE; POLYPHARMACY; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK REDUCTION; SEXUAL BEHAVIOR; SLEEP DISORDER; SYMPTOM; SYSTEMATIC REVIEW (TOPIC); TREATMENT OUTCOME; TREMOR; VITAMIN INTAKE; BEHAVIOR DISORDER; CONTROLLED CLINICAL TRIAL (TOPIC); DIFFUSE LEWY BODY DISEASE; OBSERVATIONAL STUDY; RISK; SYSTEMATIC REVIEW;

AGED; AGED, 80 AND OVER; BEHAVIOR; CHOLINESTERASE INHIBITORS; COGNITION DISORDERS; DATA INTERPRETATION, STATISTICAL; DEMENTIA; DEMENTIA, VASCULAR; DISEASE PROGRESSION; DOPAMINE AGENTS; EARLY MEDICAL INTERVENTION; HUMANS; MEMANTINE; NOOTROPIC AGENTS; PARKINSON DISEASE; PUBLICATION BIAS;

EID: 84884690918     PISSN: 14208008     EISSN: 14219824     Source Type: Journal    
DOI: 10.1159/000353892     Document Type: Review

References (75)

1. DSM-IV-TR: Diagnostic and Statistical Manual of Mental Disorders, ed 4 rev. Arlington, American Psychiatric Association, 2000
2. World Health Organization: Dementia: A Public Health Priority, 2012
3. Breteler MM, Ott A, Hofman A: The new epidemic: Frequency of dementia in the Rotterdam Study. Haemostasis 1998; 28: 117-123
4. Alzheimer's Association: 2012 Alzheimer's disease facts and figures. Alzheimers Dement 2012; 8: 131-168
5. Healthcare Insurance Board, 2013
6. Levac D, Colquhoun H, O'Brien KK: Scoping studies: Advancing the methodology. Implement Sci 2010; 5: 69
7. Arksey H, O'Malley L: Scoping studies: Towards a methodological framework. Int J Soc Res Methodol 2005; 8: 19-32
8. Kroes M, Garcia-Stewart S, Allen F, Eyssen M, Paulus D: Dementia: Which non-pharmacological interventions? KCE Reports 160C.Brussels, Belgian Health Care Knowledge Centre, 2011
9. http://bioinfo.amc.uva.nl/human-genetics/pubreminer/.
10. The Scottish Intercollegiate Guidelines Network (SIGN): Methodology Checklist 1:Systematic Reviews and Meta-Analyses. http://www.sign.ac.uk/ methodology/checklists.html (accessed June 2012
11. http://www.emea.europa.eu/ema/index.jsp?curl=pages/home/Home-Page. jsp&mid= (accessed June 2012
12. http://www.fda.gov/Drugs (accessed June 2012
13. Weinmann S, Roll S, Schwarzbach C, Vauth C, Willich SN: Effects of Ginkgo biloba in dementia: Systematic review and meta-analysis. BMC Geriatr 2010; 10: 14
14. Shah K, Qureshi SU, Johnson M, Parikh N, Schulz PE, Kunik ME: Does use of antihypertensive drugs affect the incidence or progression of dementia? A systematic review. Am J Geriatr Pharmacother 2009; 7: 250-261
15. Maidment ID, Fox CG, Boustani M, Rodriguez J, Brown RC, Katona CL: Efficacy of memantine on behavioral and psychological symptoms related to dementia: A systematic meta-analysis. Ann Pharmacother 2008; 42: 32-38
16. Birks J, Harvey RJ: Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev 2006;CD005593
17. Birks J, Harvey RJ: Donepezil for dementia due to Alzheimer's disease. Cochrane Database Syst Rev 2006;CD001190
18. Birks J, Grimley EJ, Iakovidou V, Tsolaki M: Rivastigmine for Alzheimer's disease. Cochrane Database Syst Rev 2009;CD001191
19. Maidment I, Fox C, Boustani M: Cholinesterase inhibitors for Parkinson's disease dementia. Cochrane Database Syst Rev 2006;CD004747
20. Rolinski M, Fox C, Maidment I, McShane R: Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson's disease dementia and cognitive impairment in Parkinson's disease. Cochrane Database Syst Rev 2012;CD006504
21. Cappell J, Herrmann N, Cornish S, Lanctôt KL: The pharmacoeconomics of cognitive enhancers in moderate to severe Alzheimer's disease. CNS Drugs 2010; 24: 909-927
22. Lockhart IA, Mitchell SA, Kelly S: Safety and tolerability of donepezil, rivastigmine and galantamine for patients with Alzheimer's disease: Systematic review of the 'real-world' evidence. Dement Geriatr Cogn Disord 2009; 28: 389-403
23. McKeage K: Memantine: A review of its use in moderate to severe Alzheimer's disease. CNS Drugs 2009; 23: 881-897
24. Jaturapatporn D, Isaac MG, McCleery J, Tabet N: Aspirin, steroidal and non-steroidal anti-inflammatory drugs for the treatment of Alzheimer's disease. Cochrane Database Syst Rev 2012;CD006378
25. Tabet N, Feldman H: Indomethacin for Alzheimer's disease. Cochrane Database Syst Rev 2002;CD003673
26. Tabet N, Feldman H: Ibuprofen for Alzheimer's disease. Cochrane Database Syst Rev 2003;CD004031
27. Thoonsen H, Richard E, Bentham P, Gray R, van GN, De Haan RJ, van Gool WA, Nederkoorn PJ: Aspirin in Alzheimer's disease: Increased risk of intracerebral hemorrhage: Cause for concern? Stroke 2010; 41: 2690-2692
28. López-Arrieta JM, Rodríguez JL, Sanz F: Nicotine for Alzheimer's disease. Cochrane Database Syst Rev 2001;CD001749
29. Salami O, Lyketsos C, Rao V: Treatment of sleep disturbance in Alzheimer's dementia. Int J Geriatr Psychiatry 2011; 26: 771-782
30. Rodríguez JL, Qizilbash N, López-Arrieta JM: Thiamine for Alzheimer's disease. Cochrane Database Syst Rev 2001;CD001498
31. Birks J, Evans JG: Ginkgo biloba for cognitive impairment and dementia. Cochrane Database Syst Rev 2009;CD003120
32. Man SC, Durairajan SSK, Kum WF, Lu JH, Huang JD, Cheng CF, Chung V, Xu M, Li M: Systematic review on the efficacy and safety of herbal medicines for Alzheimer's disease. J Alzheimers Dis 2008; 14: 209-223
33. Craig D, Birks J: Galantamine for vascular cognitive impairment. Cochrane Database Syst Rev 2006;CD004746
34. Craig D, Birks J: Rivastigmine for vascular cognitive impairment. Cochrane Database Syst Rev 2005;CD004744
35. Birks J, López-Arrieta JM: Nimodipine for primary degenerative, mixed and vascular dementia. Cochrane Database Syst Rev 2002;CD000147
36. Flicker L, Grimley EJ: Piracetam for dementia or cognitive impairment. Cochrane Database Syst Rev 2004;CD001011
37. Jansen SL, Forbes D, Duncan V, Morgan DG, Malouf R: Melatonin for the treatment of dementia. Cochrane Database Syst Rev 2006;CD003802
38. Malouf R, Grimley EJ: Vitamin B6 for cognition. Cochrane Database Syst Rev 2003;CD004393
39. Malouf R, Areosa SA: Vitamin B12 for cognition. Cochrane Database Syst Rev 2003;CD004394
40. Malouf R, Grimley EJ: Folic acid with or without vitamin B12 for the prevention and treatment of healthy elderly and demented people. Cochrane Database Syst Rev 2008;CD004514
41. McGuinness B, O'Hare J, Craig D, Bullock R, Malouf R, Passmore P: Statins for the treatment of dementia. Cochrane Database Syst Rev 2010;CD007514
42. Bains J, Birks JS, Dening TR: The efficacy of antidepressants in the treatment of depression in dementia. Cochrane Database Syst Rev 2002;CD003944
43. McShane R, Areosa SA, Minakaran N: Memantine for dementia. Cochrane Database Syst Rev 2006;CD003154
44. Husebo BS, Ballard C, Aarsland D: Pain treatment of agitation in patients with dementia: A systematic review. Int J Geriatr Psychiatry 2011; 26: 1012-1018
45. Kim Y, Wilkins KM, Tampi RR: Use of gabapentin in the treatment of behavioural and psychological symptoms of dementia: A review of the evidence. Drugs Aging 2008; 25: 187-196
46. Bolea-Alamanac BM, Davies SJC, Christmas DM, Baxter H, Cullum S, Nutt DJ: Cyproterone to treat aggressivity in dementia: A clinical case and systematic review. J Psychopharmacol 2011; 25: 141-145
47. de Jonghe A, Korevaar JC, van Munster BC, de Rooij SE: Effectiveness of melatonin treatment on circadian rhythm disturbances in dementia. Are there implications for delirium? A systematic review. Int J Geriatr Psychiatry 2010; 25: 1201-1208
48. Martinón TG, Fioravanti M, Grimley EJ: Trazodone for agitation in dementia. Cochrane Database Syst Rev 2004;CD004990
49. Lonergan E, Luxenberg J: Valproate preparations for agitation in dementia. Cochrane Database Syst Rev 2009;CD003945
50. Lonergan E, Luxenberg J, Colford JM, Birks J: Haloperidol for agitation in dementia. Cochrane Database Syst Rev 2002;CD002852
51. Sterke CS, Verhagen AP, van Beeck EF, van der Cammen TJ: The influence of drug use on fall incidents among nursing home residents: A systematic review. Int Psychogeriatr 2008; 20: 890-910
52. Mittal V, Kurup L, Williamson D, Muralee S, Tampi RR: Review: Risk of cerebrovascular adverse events and death in elderly patients with dementia when treated with antipsychotic medications: A literature review of evidence. Am J Alzheimers Dis Other Demen 2011; 26: 10-28
53. Gentile S: Second-generation antipsychotics in dementia: Beyond safety concerns. A clinical, systematic review of efficacy data from randomised controlled trials. Psychopharmacology 2010; 212: 119-129
54. Konovalov S, Muralee S, Tampi RR: Anticonvulsants for the treatment of behavioral and psychological symptoms of dementia: A literature review. Int Psychogeriatr 2008; 20: 293-308
55. Seitz DP, Adunuri N, Gill SS, Gruneir A, Herrmann N, Rochon P: Antidepressants for agitation and psychosis in dementia. Cochrane Database Syst Rev 2011;CD008191
56. Henry G, Williamson D, Tampi R: Efficacy and tolerability of antidepressants in the treatment of behavioral and psychological symptoms of dementia, a literature review of evidence. Am J Alzheimers Dis Other Demen 2011; 26: 169-183
57. Howard R, McShane R, Lindesay J, Ritchie C, Baldwin A, Barber R, Burns A, Dening T, Findlay D, Holmes C, Hughes A, Jacoby R, Jones R, Jones R, McKeith I, Macharouthu A, O'Brien J, Passmore P, Sheehan B, Juszczak E, Katona C, Hills R, Knapp M, Ballard C, Brown R, Banerjee S, Onions C, Griffin M, Adams J, Gray R, Johnson T, Bentham P, Phillips P: Donepezil and memantine for moderate-to-severe Alzheimer's disease. N Engl J Med 2012; 366: 893-903
58. Dal FG, Palermo MT, Donohue JE, Karagiozis H, Zonderman AB, Kawas CH: Depressive symptoms, sex, and risk for Alzheimer's disease. Ann Neurol 2005; 57: 381-387
59. Fick DM, Agostini JV, Inouye SK: Delirium superimposed on dementia: A systematic review. J Am Geriatr Soc 2002; 50: 1723-1732
60. Reuben DB, Tinetti ME: Goal-oriented patient care -an alternative health outcomes paradigm. N Engl J Med 2012; 366: 777-779
61. Ballard C, Gauthier S, Corbett A, Brayne C, Aarsland D, Jones E: Alzheimer's disease. Lancet 2011; 377: 1019-1031
62. California Workgroup on Guidelines for Alzheimer's Disease Management: Guideline for Alzheimer's Disease Management. Chicago, Alzheimer's Association, 2008
63. Scottish Intercollegiate Guidelines Network: Management of Patients with Dementia. Edinburgh, 2013, pp 13-20
64. Gerber S, Tallon D, Trelle S, Schneider M, Juni P, Egger M: Bibliographic study showed improving methodology of meta-analyses published in leading journals 1993-2002. J Clin Epidemiol 2007; 60: 773-780
65. Hanson LC, Ersek M, Gilliam R, Carey TS: Oral feeding options for people with dementia: A systematic review. J Am Geriatr Soc 2011; 59: 463-472
66. Guay DR: Inappropriate sexual behaviors in cognitively impaired older individuals. Am J Geriatr Pharmacother 2008; 6: 269-288
67. Hogervorst E, Yaffe K, Richards M, Huppert FAH: Hormone replacement therapy to maintain cognitive function in women with dementia. Cochrane Database Syst Rev 2009;CD003799
68. Rodda J, Morgan S, Walker Z: Are cholinesterase inhibitors effective in the management of the behavioral and psychological symptoms of dementia in Alzheimer's disease? A systematic review of randomized, placebocontrolled trials of donepezil, rivastigmine and galantamine. Int Psychogeriatr 2009; 21: 813-824
69. Grossberg GT, Pejovic V, Miller ML, Graham SM: Memantine therapy of behavioral symptoms in communitydwelling patients with moderate to severe Alzheimer's disease. Dement Geriatr Cogn Disord 2009; 27: 164-172
70. Schneider LS, Dagerman KS, Higgins JPT, McShane R: Lack of evidence for the efficacy of memantine in mild Alzheimer disease. Arch Neurol 2011; 68: 991-998
71. Birks J, Flicker L: Selegiline for Alzheimer's disease. Cochrane Database Syst Rev 2003;CD000442
72. El-Kareem-Nasr IMG, Quinn R, Tabet N: Vitamin E for Alzheimer's disease and mild cognitive impairment. Cochrane Database Syst Rev 2008;CD002854
73. Wild R, Pettit T, Burns A: Cholinesterase inhibitors for dementia with Lewy bodies. Cochrane Database Syst Rev 2003;CD003672
74. Levine DA, Langa KM: Vascular cognitive impairment: Disease mechanisms and therapeutic implications. Neurotherapeutics 2011; 8: 361-373
75. Malouf R, Birks J: Donepezil for vascular cognitive impairment. Cochrane Database Syst Rev 2004;CD004395